A pharmacokinetic sub-study found that TAMP-mediated gemcitabine reduced systemic drug exposure in patients with locally advanced pancreatic cancer.
Commentary|Videos|May 31, 2026
Dr King on the Efficacy of Daraxonrasib in Previously Treated mPDAC From RASolute 302
Author(s)Daniel King, MD, PhD
Fact checked by: Ashling Wahner , Chris Ryan
Daniel King, MD, PhD, discusses the implications of the RASolute 302 study of daraxonrasib in previously treated metastatic pancreatic adenocarcinoma.
Advertisement
“Many are calling it a breakthrough, and I do think it has strong potential to become practice-changing.”
Daniel King, MD, PhD, director of Research and Development at the Center for Genomic Medicine at Northwell Health Cancer Institute, discussed key efficacy data from the phase 3 RASolute 302 trial (NCT06625320) investigating daraxonrasib (RMC-6236) in patients with previously treated metastatic pancreatic adenocarcinoma.
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The zanidatamab-plus-chemotherapy arm met its overall survival end point at the second interim analysis of the phase 3 HERIZON-GEA-01 trial.
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
5